相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
招募中
1
100.0%
暂无批准数据
- A single-center randomized controlled trial found that combined TAP and rectus sheath blocks with liposomal bupivacaine reduced 48-hour perioperative opioid consumption by 29.17% versus no block in patients aged 70 and older. - Mean morphine-equivalent use was 17 mg with liposomal bupivacaine, 18 mg with plain bupivacaine and 24 mg in controls, with estimated mean differences of -7.24 mg and -5.53 mg respectively. - Only 2.0% of liposomal bupivacaine patients required rescue analgesia versus 18.4% of controls, and time to first ambulation was shortened by 5.86 hours. - Postoperative hospital stay fell to a median of 1 day in both block groups versus 2 days in controls, with no increase in adverse events and high analgesia satisfaction.
- A 52-member expert panel has published 2026 evidence-graded recommendations for immune checkpoint inhibitor-associated myocarditis, a rare complication with mortality of 37 to 50 percent. - Combination immunotherapy carries substantially higher risk, with six-month myocarditis incidence of 1.6 percent for PD-1 plus CTLA-4 regimens versus 0.2 to 0.4 percent for monotherapy. - Thymic imaging is now formally incorporated into risk stratification, as thymoma patients show an odds ratio of 32 for myocarditis and earlier onset at a median of 21 days. - Treatment emphasizes immediate checkpoint inhibitor cessation and glucocorticoids within 24 hours, with abatacept plus ruxolitinib reducing mortality to 3 percent versus 60 percent with steroids alone.
